Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Too many "exhausted" T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job.

16 Aug 2021

Researchers develop a new way to tag tumor cells to understand cancer treatment resistance

Despite tremendous advances in medicine, tumors are challenging to cure because they are made up of heterogeneous cells.

13 Aug 2021

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

Shuo Ma, MD, '00 PhD, associate professor of Medicine in the Division of Hematology and Oncology, was co-first author of the clinical trial published in Blood.

5 Aug 2021

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors.

29 Jul 2021

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

21 Jul 2021

Protein markers in chronic lymphocytic leukemia may help determine patients' prognoses

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types.

21 Jul 2021

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring

According to researchers at Marshall University, a maternal diet rich in Omega-3 fatty acids protects from breast cancer development in offspring.

28 Jun 2021

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

A recent study discusses the findings of a study on patients with hematologic cancers who received convalescent plasma therapy following their diagnosis of COVID-19.

21 Jun 2021

Extensive cancer research data to be presented at the 2021 ASCO Annual Meeting

Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8.

20 May 2021

Machine learning technique detects epigenetic drivers of cancers

Scientists have made major advances in understanding and developing treatments for many cancers by identifying genetic mutations that drive the disease.

10 May 2021

New NCCN patient guidelines on anemia and neutropenia published

The National Comprehensive Cancer Network announced today the publication of new NCCN Guidelines for Patients: Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the NCCN Foundation and endorsed by The Leukemia and Lymphoma Society (LLS).

3 May 2021

Yale scientists uncover common mechanism that promotes autoimmune diseases and blood cancers

In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).

19 Apr 2021

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

17 Apr 2021

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

The National Comprehensive Cancer Network and the NCCN Foundation today announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards Program.

15 Apr 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

If I have cancer, dementia or MS, should i get the covid vaccine?

As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines' appropriateness for older adults with various illnesses.

27 Jan 2021

Infusion of convalescent blood plasma benefits patient with severe COVID-19

A 72-year-old woman was hospitalized with severe COVID-19 disease, 33 days after the onset of symptoms.

22 Jan 2021

MDC researchers develop a potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

11 Jan 2021

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020